secwatch.observer — SEC 8-K summary
======================================

Issuer:     NEKTAR THERAPEUTICS (NKTR)
CIK:        0000906709
Form:       8-K
Filed at:   2026-09-25T11:00:23+00:00
Accession:  0001213900-26-103215
Event type: litigation
Sentiment:  positive
Materiality: 0.75
Item codes: 8.01
LLM model:  deepseek-v4.1-flash:cloud@v2

Nektar wins $90M jury verdict against Eli Lilly in rezpegaldesleukin license dispute
--------------------------------------------------------------------------------

- Jury found Lilly breached the implied covenant of good faith and fair dealing in the rezpegaldesleukin license deal; verdict returned Sept 24, 2026 (N.D. Cal. 3:23-cv-03943-JD).
- Jury awarded Nektar $90 million in damages plus interest, with the interest amount to be determined by the District Court.
- Nektar filed the complaint in August 2023 alleging breach of contract and breach of implied covenant; jury trial began September 8, 2026.
- Verdict remains subject to post-trial proceedings and any resulting judgment may be subject to appeal.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/906709/000121390026103215/0001213900-26-103215-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/906709/000121390026103215/ea0306370-8k_nektar.htm
  HTML page:      https://secwatch.observer/filing/0001213900-26-103215

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer